Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label
tabling member	label

Search

993447

registered interest
date	23/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Flour: Folic Acid
house id	1
legislature	25259 pref label House of Commons
question text	What progress he has made on implementing proposals for the mandatory fortification of flour with folic acid.
tabling member constituency	Cumbernauld, Kilsyth and Kirkintilloch East
tabling member printed	Stuart C. McDonald
uin	907229
answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>The Government is continuing to review advice from our expert advisory groups on safe levels of folate intake. Alongside this, we will be issuing a public consultation on the issue of adding folic acid to flour. This will explore this complex issue in detail and allow us to take an informed decision on whether to introduce mandatory fortification of flour. We will announce the date for the consultation soon.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:43:47 answering member 4067 label Biography information for Steve Brine
tabling member	4393 label Biography information for Stuart C McDonald

993448

registered interest
date	23/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Foetal Alcohol Spectrum Disorder
house id	1
legislature	25259 pref label House of Commons
question text	What assessment he has made of the proportion of children born in the UK with foetal alcohol spectrum disorders in each of the last five years.
tabling member constituency	Sefton Central
tabling member printed	Bill Esterson
uin	907231
answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>Foetal alcohol syndrome disorders can have a significant impact on the early years development of children, their behaviours and their life chances.</p><p>Public Health England collects some data on fetal alcohol sydrome, but we recognise that this data does not reflect the range of fetal alcohol spectrum disorders (FASD), as these are very difficult to diagnose. That is why we are engaging experts and those affected by FASD to explore what more could be done to improve our understanding.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:44:55 answering member 4067 label Biography information for Steve Brine
tabling member	4061 label Biography information for Bill Esterson

990259

registered interest
date	18/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Buprenorphine
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect on access to Buprenorphine of the recent increase in the price of that drug.
tabling member constituency	Leicester South
tabling member printed	Jonathan Ashworth
uin	181221
answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>As a consequence of a supply issue affecting buprenorphine earlier this year, some suppliers of buprenorphine have run out of stock and the market price has been increasing since May 2018. Although supplies continued to remain available from other suppliers, we are aware that some may have struggled to support the increase in demand at short notice. The delivery issues were resolved quickly and the overall supply of buprenorphine tablets improved shortly afterwards.</p><p> </p><p>Since this period, the Department has remained in regular contact with all United Kingdom licensed suppliers of buprenorphine and has been working closely with them to monitor their supply position. Based on these conversations, we have been assured that the available supplies are sufficient to meet the usual UK requirements for this drug. The Department continues to monitor this very closely.</p><p> </p><p>The increased purchase price is reflected in the reimbursement price paid to pharmacies, to ensure that supplies remain available to patients. The market for buprenorphine has generally been competitive and we expect the supply situation to improve over the coming weeks which is likely to result in an increasingly competitive market.</p><p><strong> </strong></p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:41:59 answering member 4067 label Biography information for Steve Brine
tabling member	4244 label Biography information for Jonathan Ashworth

990352

registered interest
date	18/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will take steps to allow patients to have access to NHS doctors willing to prescribe cannabis-based medicine in cases where their NHS doctor is unwilling to do so.
tabling member constituency	Cardiff West
tabling member printed	Kevin Brennan
uin	181179
answer	answer is ministerial correction date of answer 23/10/2018 answer text <p>NHS England expects that cannabis-based products for medicinal use should only be prescribed for indications where there is clear evidence of benefit, and in patients where there is a clinical need which cannot be met by a licensed medicine and, where established treatment options have been exhausted.</p><p> </p><p>The decision to prescribe these unlicensed medicines must be made by a specialist doctor – not a general practitioner. These doctors focus on one field of medicine such as neurology or paediatrics and are listed on the General Medical Council’s specialist register. They must make decisions on prescribing cannabis-based products for medicinal use on a case by case basis, and only when the patient has an unmet special clinical need that cannot be met by licensed products. In addition, a specialist on the General Medical Council Register should only prescribe within their own area of practice, and the decision to prescribe should be agreed by the multidisciplinary team.</p><p> </p><p>NHS England, the British Paediatric Neurology Association and the Royal College of Physicians will provide clinical advice to doctors ahead of the law change. The National Institute for Health and Care Excellence has been commissioned to develop more detailed guidelines for clinicians in the longer term.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/10/2018 16:43:24 answering member 4067 label Biography information for Steve Brine
tabling member	1400 label Biography information for Kevin Brennan